Research ExplorerPublicationsVariant of hepatitis B virus with primary resistance to adef...

Variant of hepatitis B virus with primary resistance to adefovir.

Standard

Variant of hepatitis B virus with primary resistance to adefovir. / Schildgen, Oliver; Sirma, Hüseyin; Funk, Anneke; Olotu, Cynthia; Wend, Ulrike C; Hartmann, Heinz; Helm, Martin; Rockstroh, Jürgen K; Willems, Wulf R; Will, Hans; Gerlich, Wolfram H.

In: NEW ENGL J MED, Vol. 354, No. 17, 17, 2006, p. 1807-1812.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schildgen, O, Sirma, H, Funk, A, Olotu, C, Wend, UC, Hartmann, H, Helm, M, Rockstroh, JK, Willems, WR, Will, H & Gerlich, WH 2006, 'Variant of hepatitis B virus with primary resistance to adefovir.', NEW ENGL J MED, vol. 354, no. 17, 17, pp. 1807-1812. <http://www.ncbi.nlm.nih.gov/pubmed/16641397?dopt=Citation>

APA

Schildgen, O., Sirma, H., Funk, A., Olotu, C., Wend, U. C., Hartmann, H., Helm, M., Rockstroh, J. K., Willems, W. R., Will, H., & Gerlich, W. H. (2006). Variant of hepatitis B virus with primary resistance to adefovir. NEW ENGL J MED, 354(17), 1807-1812. [17]. http://www.ncbi.nlm.nih.gov/pubmed/16641397?dopt=Citation

Vancouver

Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H et al. Variant of hepatitis B virus with primary resistance to adefovir. NEW ENGL J MED. 2006;354(17):1807-1812. 17.

Bibtex

@article{b479f64903884a759a8f7bf809f0f57a,
title = "Variant of hepatitis B virus with primary resistance to adefovir.",
abstract = "The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.",
author = "Oliver Schildgen and H{\"u}seyin Sirma and Anneke Funk and Cynthia Olotu and Wend, {Ulrike C} and Heinz Hartmann and Martin Helm and Rockstroh, {J{\"u}rgen K} and Willems, {Wulf R} and Hans Will and Gerlich, {Wolfram H}",
year = "2006",
language = "English",
volume = "354",
pages = "1807--1812",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

RIS

TY - JOUR

T1 - Variant of hepatitis B virus with primary resistance to adefovir.

AU - Schildgen, Oliver

AU - Sirma, Hüseyin

AU - Funk, Anneke

AU - Olotu, Cynthia

AU - Wend, Ulrike C

AU - Hartmann, Heinz

AU - Helm, Martin

AU - Rockstroh, Jürgen K

AU - Willems, Wulf R

AU - Will, Hans

AU - Gerlich, Wolfram H

PY - 2006

Y1 - 2006

N2 - The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.

AB - The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.

M3 - SCORING: Journal article

VL - 354

SP - 1807

EP - 1812

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 17

M1 - 17

ER -